Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Oct 21, 2018; 24(39): 4472-4481
Published online Oct 21, 2018. doi: 10.3748/wjg.v24.i39.4472
Table 1 Demographic, endoscopic and histologic characteristics of the study population
Patient dataAll sample (n = 386)HGD (n = 12)Non-HGD (n = 367)
Age at study inclusion60.0 (13.1) [61.1, 18.4-89.6]66.3 (12.8) [66.6, 42.4-85.8]59.8 (13.2) [60.6, 18.4-89.6]
Gender - male268 (69.43)9 (75)253 (68.94)
Number of endoscopies per patient2.5 (2.0) [2, 1-17]6.6 (2.6) [7, 3-11]2.4 (1.7) [2, 1-10]b
Patients with multiple endoscopies245 (63.47%)12 (100)227 (61.9)a
Circumferential extent of BE (cm)3.3 (3.3) [2, 0-19]4.5 (2.92) [4.5, 1-11]3.2 (3.23) [2, 0-19]
Maximal extent of BE (cm)4.4 (3.2) [3, 0.2-20]6.0 (3.22) [6, 2-14]4.25 (3.17) [3, 0.2-20]a
Presence of endoscopic abnormalities56 (14.51)8 (66.67)44 (11.99)b
Ultra-short BE segment (BE < 1 cm)28 (7.43)0 (0)28 (7.8)
Short BE segment (1 cm ≤ BE < 3 cm)124 (32.89)2 (18.18)122 (33.98)
Long BE segment (BE ≥ 3 cm)225 (59.68)9 (81.82)209 (58.22)
Worst degree of dysplasia
Esophageal adenocarcinoma6 (1.6)
Intramucosal carcinoma1 (0.3)
High grade dysplasia12 (3.1)
Low grade dysplasia19 (4.9)
Table 2 Overall cancer cases, stratified to pre-study and incident cases n (%)
Pre-study cancersIncident cancersLifetime cancers
Esophagus2 (0.5)24 (1)6 (1.6)
Cardia2 (0.5)3 (0.8)5 (1.3)
Stomach3 (0.8)0 (0)3 (0.8)
Colorectal cancer9 (2.3)1 (0.3)10 (2.6)
Small intestine1 (0.3)0 (0)1 (0.3)
Cholangiocarcinoma1 (0.3)0 (0)1 (0.3)
Pancreas0 (0)2 (0.5)2 (0.5)
Bladder5 (1.3)4 (1)9 (2.3)
Prostate11 (2.8)0 (0)11 (2.8)
Kidney2 (0.5)2 (0.5)4 (1)
Hematologic cancer8 (2.07)4 (1)12 (3.1)
Skin4 (1)2 (0.5)6 (1.6)
Breast4 (1)2 (0.5)6 (1.6)
Thyroid3 (0.8)0 (0)3 (0.8)
Lung0 (0)2 (0.5)2 (0.5)
Kaposi0 (0)1 (0.3)1 (0.3)
Laryngeal3 (0.8)0 (0)3 (0.8)
Cervical1 (0.3)0 (0)1 (0.3)
Any type of cancer59 (15.3)27 (7)86 in 75 (19.4) patients1
BE cancer3 (0.8)7 (1.8)10 in 10 (2.6) patients
Non-BE cancers56 (14.5)20 (5.2)76 in 65 (16.8) patients
Table 3 Univariate and multivariable Cox regression for the prediction of non- Barrett’s esophagus cancers
n = 379 (excluding EAC and IMC)HR (95%CI)Adjusted HR (95%CI)
Age at study inclusion11.11 (0.99-1.24)1.07 (0.95-1.21)
Gender - male2.19 (0.63-7.55)
Number of endoscopies per patient0.82 (0.59-1.12)0.72 (0.50-1.03)
Presence of endoscopic abnormalities1.19 (0.34-4.09)
Circumferential extent of BE (cm)0.99 (0.79-1.26)
Maximal extent of BE (cm)1.06 (0.92-1.23)
Ultra-short segment (BE < 1 cm)1
Short segment (1 cm ≤ BE < 3 cm)0.96 (0.11-8.24)
Long segment (BE ≥ 3 cm)0.99 (0.13-7.85)
Pre-study cancer history2.58 (0.92-7.25)2.12 (0.73-6.17)
HGD vs non-HGD3.40 (0.78-14.84)8.32 (1.35-51.33)a
Table 4 Univariate and multivariable Cox regression for the prediction of any cancer
n = 386 (including EAC and IMC)HR (95%CI)Adjusted HR (95%CI)
Age at study inclusion11.09 (0.99-1.20)1.08 (0.97-1.21)
Gender - male2.29 (0.79-6.67)
Number of endoscopies per patient1.11 (0.96-1.29)0.99 (0.82-1.21)
Presence of endoscopic abnormalities2.27 (0.95-5.44)
Circumferential extent of BE (cm)1.10 (0.96-1.26)
Maximal extent of BE (cm)1.12 (1.008-1.24)a1.13 (1.000-1.27)
Ultra-short segment (BE < 1cm)1
Short segment (1 cm ≤ BE < 3 cm)0.97 (0.11-8.30)
Long segment (BE ≥ 3 cm)1.77 (0.23-13.34)
Pre-study cancer history2.15 (0.86-5.39)
HGD vs non-HGD6.33 (2.37-16.91)b4.28 (1.17-15.76)a